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Regular Article
IMMUNOBIOLOGY
CD1411 dendritic cells produce prominent amounts of IFN-a after
dsRNA recognition and can be targeted via DEC-205 in humanized mice
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Key Points
• Human CD1411 cDCs not
only produce IL-12 but also
yield large amounts of IFN-a
after TLR3 stimulation with
synthetic dsRNA.
• Targeting of antigen to DEC-
205 and synthetic dsRNA as
adjuvant for CD1411 cDCs
maturation induces CD41
T cell responses in
humanized mice.
Functional differences between human dendritic cell (DC) subsets and the potential
benefits of targeting themwith vaccines remain poorly defined. Herewedescribe thatmice
with reconstituted human immune system components (huNSG mice) develop all human
conventional and plasmacytoid DC compartments in lymphoid organs. Testing different
Toll-like receptor agonists for DCmaturation in vivo, we found that IL-12p70 and interferon
(IFN)-a production correlated with the maturation of CD1411 (BDCA31) conventional DCs
in huNSG mice. Furthermore, depletion of CD1411 DCs before stimulation significantly
reduced IFN-a levels in vivo. This DC subset produced similar total amounts but different
subtypes of IFN-a in response to synthetic double-stranded RNA compared with
plasmacytoid DCs in response to a single-stranded RNA equivalent. Moreover, synthetic
double-stranded RNA as adjuvant and antigen targeting to the endocytic receptor DEC-
205, a combination that focuses antigen presentation for T-cell priming on CD1411 DCs,
stimulated antigen-specific human CD41 T-cell responses. Thus, the human CD1411 DC
subset is a prominent source of IFN-a and interleukin-12 production and should be
further evaluated for vaccine development. (Blood. 2013;121(25):5034-5044)
Introduction
Dendritic cells (DCs) are antigen-presenting cells that get activated
upon the sensing of pathogens and induce robust innate and adap-
tive immune responses. This so-called maturation leads to major
histocompatibility complex and costimulatory molecule up-regulation,
enhanced migration to secondary lymphoid tissues, and cytokine
production by DCs.1,2 In humans, the major DC subsets in the
steady state are conventional DCs (cDCs) and plasmacytoid DCs
(pDCs),3 which differ in their expression of surface markers,
Toll-like receptors (TLRs), and in the cytokines produced after
activation. cDCs are positive for CD11c and carry either CD1c
(BDCA1) or CD141 (BDCA3).4,5 CD1c1 cDCs express TLR1
through TLR8 and TLR10, which enable them to respond to
pathogen-associated molecular patterns such as double-stranded (ds)
and single-stranded (ss) RNA.6-8 The small subset of CD1c2CD1411
cDCs expresses TLR1, 2, 3, 6, 8, and 10 and efﬁciently cross-presents
antigens to CD81 T cells.8-12 Upon activation, cDCs are primarily
known to secrete interleukin (IL)-12, tumor necrosis factor (TNF)-
a, and IL-6. pDCs, on the other hand, are CD11c negative and
CD123, CD303 (BDCA2), and CD304 (BDCA4) positive.5 In contrast
to cDCs, they sense ssRNA and unmethylated DNA by TLR7 and
TLR9, respectively.6 In response, they secrete type I interferons
(IFNs) and play an important role in immune reactions to viral
infection. pDCs also express TLR1, 6 and 10.7 Although the TLR
expression of human DC subsets has been characterized in vitro,
human pDC and cDC responses to TLR agonists have just begun to
be investigated in vivo. Of note, efﬁcient maturation of human DCs
by adjuvants that induce signaling of TLRs or pathogen-associated
molecular pattern receptors seems necessary for successful vaccination.
Mice reconstituted with human immune system components are
a valuable tool to study human immune cells in vivo as well as to
characterize the infection and immune response to pathogens with
a strictly human tropism in a small animal model.13,14 The 2 major
strains that are used for these studies are either mice deﬁcient in
recombination activating gene 2 (Rag2) and the cytokine receptor
common g chain on BALB/c background (BALB/c Rag22/2gc
2/2)
or gc-deﬁcient, nonobese diabetic (NOD) mice with the Prkdc
scid
mutation (NOD-scid gc
2/2, [NSG]). On both genetic backgrounds,
injection of CD341 human hematopoietic stem or progenitor cells
reconstitutes all major leukocyte subsets, including CD11c1 cDCs
as well as CD1231 pDCs.15-18 Although the in vivo presence
of reconstituted human DC subsets in NSG mice reconstituted with
human immune system components (huNSG) has been described,19
the functions of these human DC subsets in these models have not
been explored in detail.
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Here, we describe the composition and organ distribution of the DC
compartment in huNSG mice. Furthermore, we study their maturation
by different TLR agonists in vivo by monitoring maturation marker
expression and cytokine secretion. Surprisingly, we found that matura-
tion of CD1411 cDCs correlates with the greatest production of
both IL-12p70 and IFN-a in vivo and that enriched CD1411 DC
populations produce similar amounts of IFN-a upon synthetic
dsRNA exposure as pDCs after recognition of a ssRNA surrogate.
Depletion of CD1411 cDCs in huNSG mice before stimulation
signiﬁcantly reduced IFN-a production in vivo. Accordingly, human
donor-derived CD1411 cDCs produced IFN-a after stimulation
with synthetic dsRNA. Furthermore, synthetic dsRNA as adjuvant
and targeting antigen to the DEC-205 receptor, a combination that
matures antigen-loaded CD1411DCs, led to the priming of antigen-
speciﬁc human CD41 T-cell responses after vaccination. Our study,
therefore, identiﬁes the CD1411 cDC subset as a prominent source
of IFN-a after dsRNA recognition and competent to prime T-cell
responses.
Materials and methods
Generation of HuNSG mice and cell isolation
NOD, Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG), mice were obtained from The
Jackson Laboratory. HuNSG mice were generated as described by
reconstitution with human fetal liver2derived CD341 hematopoietic
progenitor cells (Advanced Bioscience Resources).20 Animal protocols
were approved by the Cantonal Veterinary Ofﬁce Zu¨rich.
Cells from heparinized blood were obtained after centrifugation for
10 minutes at 400g and erythrocyte lysis. Serum was processed on BD
Microtainers (BD Biosciences). Spleens were digested in Hanks balanced
salt solution with CaCl2/MgCl2 containing 0.4 mg/mL collagenase D (Roche
Diagnostics) and 20 mg/mL DNAse (Roche Diagnostics) before mashing
and erythrocytes lysis. Bone marrow (BM) cells were ﬂushed from excised
femurs.
TLR agonists
CpG ODN 2216 was purchased from InvivoGen, glycopyranosyl lipid
adjuvant (GLA), IDC 1001 from the Infectious Disease Research Institute,
and R848 from Enzo Life Sciences. PolyICLC was obtained from Oncovir
Inc. and protamine/RNA from S. Pascolo (RNA: AGUGUUAUUCUU
GUAUGG, 1:4 protamine).
Flow cytometry
Per sample, 43 106 cells were stained. Antibodies used are described in the
supplemental information; see the Blood website). For intracellular cytokine
staining, we used the BD Biosciences Cytoﬁx/Cytoperm Plus kit. Samples
were acquired on a BD LSRFortessa with the use of FACS Diva software
(BD Biosciences). Analysis was performed with FlowJo Software (Tristar).
Histology
Spleens were frozen in OCT medium, sectioned at 6-8 mm, and
immunostained for 1 hour. Sections were washed in phosphate-buffered
saline (PBS) and mounted in Aqua Poly/Mount (Polysciences).
Cytokine ELISAs
IFN-a pan, IFN-a2, IL-12p70, and IFN-g enzyme-linked immunosorbent
assay (ELISA) kits were purchased from Mabtech.
Preparation of human PBMCs and DC isolation
Preparation of human PBMCs and DC isolation are described in the sup-
plemental Methods.
Quantitative polymerase chain reaction
RNA was isolated with the RNeasy Micro Kit (QIAGEN). Reverse-
transcription and quantitative polymerase chain reactions were performed
as described21 and run on a BIO-RAD iCycler IQ.
Vaccination experiments
aDEC-205-Alexa647 or isotype-Alexa647 monoclonal antibodies (mAbs)
were a kind gift of Dr. C. Cheong (Montreal, Canada). aDEC-205-EBNA1
or isotype-EBNA1, IFN-g enzyme enzyme-linked immunospot, and
peptide libraries have been described.22
Generation of EBNA1 specific T-cell clones
IFN-g2secreting cells were enriched from splenocytes of vaccinated
huNSG mice by an IFN-g2secretion assay/cell enrichment and detection
kit (Miltenyi Biotec) and cloned by limiting dilution as described.23
Functional T-cell assays are described in the supplemental Methods.
Statistical analysis
Mann-Whitney U tests were performed for analysis in Figures 2, 3, 4, and
7. Data in Figures 5 and 6 were analyzed by paired t test using GraphPad
Prism Software (Version 5.0a).
Results
Robust reconstitution of all human DC subsets in huNSG mice
We reconstituted newborn NSG mice with CD341 human fetal
liver2derived hematopoietic progenitor cells and analyzed the DC
compartment 4 months later. By ﬂow cytometry staining, we deﬁned
human DCs as being positive for human CD45 and HLA-DR but
negative for lineage markers CD3 (T cells), CD19 (B cells), CD56
(NK cells), CD14 (mainly monocytes), and CD16 (mainly NK cells;
supplemental Figure 1A). We subdivided the CD11c1 cDC pop-
ulation into CD1c or CD141-positive cells. The pDC subset was
deﬁned as CD11c2CD3031 (Figure 1A). We detected all 3 human
DC subsets in spleen (Figure 1A), BM (Figure 1B), and blood
(Figure 1C). On average, DCs comprised 3% of reconstituted cells. In
spleen and BM, most cDCs were CD1c1, whereas in blood CD1411
cDCs predominated. The greatest percentage of pDCs was located in
the BM, exceeding 2% of human CD451 cells in most mice. Those
trends reﬂected the absolute numbers of DC subsets per spleen
(Figure 1A), femur (Figure 1B), or milliliters of blood (Figure 1C).
Per spleen, we detected on average 300 000 cDCs and 200 000 pDCs.
We analyzed the distribution of human DCs in spleens of huNSG
mice by immunoﬂuorescence microscopy on histological sections. As
in ﬂow cytometric staining (supplemental Figure 1B-C), we detected
both DEC-205 high and low cells. They were of DC morphology and
in T-cell zones of white pulp areas (Figure 1D).We could not subdivide
those by CD1c and CD141 because the staining for these markers was
unspeciﬁc.
In conclusion, we identiﬁed the main constitutive human DC
subsets in primary and secondary lymphoid organs of huNSG mice.
Interestingly, the frequency of the CD1411 DCs in blood and BM of
huNSG mice is greater than in human blood and BM.8 Furthermore,
the reconstituted cDCs in huNSG mice home to similar areas as their
counterparts in human spleen.24
Ligation of RNA receptors matures human conventional and
plasmacytoid DCs in vivo
To test the functional competence of reconstituted DCs in huNSG
mice, we analyzed whether intraperitoneal injection of TLR agonists
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matured human DCs in vivo. We used the TLR3 ligand poly-
ICLC,25,26 the TLR4 ligand GLA,27 the TLR7/8 ligands R848,28 and
protamine/RNA,29 as well as CpG as a TLR9 agonist.30 After 14
hours (supplemental Figure 2A), we sacriﬁced the mice and assessed
surface levels of maturation markers (CD86, CD83, CD274, CD40,
and HLA-DR) on the different splenic DC subsets (supplemental
Figure 1D). Both cDC subsets signiﬁcantly up-regulated maturation
markers when injected with polyICLC, in line with TLR3 expression
on CD1c1 and CD1411 cDCs in human (Figure 2A and supplemental
Figure 2B). In contrast, only CD1c1 cDCs should have TLR4.
Accordingly, only this cDC subset matured signiﬁcantly in response
to GLA. R848 not only matured cDCs but also up-regulated CD40,
CD86, CD274, and HLA-DR expression on pDCs signiﬁcantly, albeit
to a lesser extent (Figure 2A). Neither protamine/RNA nor CpG
ODN2216 phenotypically matured human DCs (Figure 2A), even
though those compounds induced, albeit weak, murine cytokine
production by DCs in nonreconstituted NSG mice (supplemental
Figure 3A). With both being particulate formulations, however,
their bioactivity might improve with intravenous compared with
intraperitoneal injection. Changes in CD83, CD86, and CD274
expression were greatest after the injection of polyICLC and R848,
whereas CD40 and HLA-DR expression was less affected by the
TLR agonists (Figure 2A). Furthermore, CD86 was most dramati-
cally up-regulated on CD1411 DCs after polyICLC stimulation
(.10-fold). In summary, the effect of a given TLR agonist depends
on the DC subset as well as on the maturation marker analyzed.
Figure 1. Human DC subsets in huNSG mice. (A) Flow cytometric staining of CD11c2, CD3031 pDCs, or CD1c1 and CD1411 on CD11c1 cDCs of the spleen (left).
Samples were pregated as singlet, live cells positive for hCD45 and HLA-DR and negative for lineage, CD14, and CD16. Percentages of those subsets in relation to live,
singlet, human CD451 cells are shown in the middle. The numbers on top of the data points indicate the average percentage of human CD45-positive cells for each analyzed
DC subset. Absolute numbers of DC populations are shown on the right. Graphs represent data from mice from 4 independent reconstitutions. Each data point represents one
individually analyzed mouse. (B) Same as in panel A for DC subsets of the BM. (C) Same as in panel A for DC subsets of the blood. (D) Immunofluoresence microscopy for
DC markers on spleen sections. DEC-205 in red as DC-marker, CD20 in green as B-cell marker, and CD3 in blue as T cell marker.
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In addition, we chose the stimulus most efﬁcacious for re-
constituted cDCs in this setting, polyICLC, to study DC maturation
in tissue sections. We observed an increase of DEC-2051 cells in
spleens of polyICLC-treated mice (Figure 2B). Whereas unstimu-
lated spleens only displayed small areas of DEC-2051 DC-LAMP1
cDCs, DC-LAMP1 mature cDC numbers increased dramatically
after the injection of polyICLC (Figure 2B). Of note, mature cDCs
were preferentially found in T-cell zones of splenic white pulp.
In general, all reconstituted constitutive DC compartments of
huNSGmice matured in response to TLR agonists in vivo. However,
only those targeting RNA receptors (TLR3/7/8) induced robust
maturation of cDCs and pDCs.
Human conventional DC populations mature slowly in response
to TLR agonists in vivo
Next, we characterized the kinetics of DC maturation in huNSG
mice after the injection of polyICLC. Maturation markers were
maximally up-regulated at 11 to 14 hours (Figure 3A-B). Again,
we detected the greatest up-regulation of CD86 on CD1411 cDCs,
and pDCs were only minimally activated (Figures 2A and 3A). In
general, the kinetics of DC maturation in huNSG mice resemble
activation of human DCs in vitro, whereas TLR agonists activate
mouse DCs considerably faster.25
Only stimulation of RNA receptors elicits cytokine production
by human DCs in vivo
As a functional readout for DC activation, we measured human
cytokines in the serum of huNSG mice at different time points
after polyICLC injection. We analyzed IL-12p70 as a cDC
signature cytokine and IFN-a, which is secreted at high levels by
activated pDCs.6 Concentrations of those cytokines peaked 11
hours after injection (Figure 3C). Remarkably, they consistently
reached approximately 1 ng/mL for IL-12p70 and up to 25 ng/mL
for IFN-a.
In addition, we monitored cytokine production after we injected
different TLR agonists. In line with DC maturation, injection of
polyICLC or R848 induced strong cytokine production, whereas
protamine/RNA and CpG did not (Figure 3D). Serum IL-12 and
IFN-a concentrations varied after polyICLC injection between
experiments, possibly resulting from hematopoietic progenitor cell
donor variation or differences in the used TLR agonist batches.
These cytokines, however, were coregulated in individual huNSG
Figure 2. Maturation of human DC subsets upon TLR ligand injection in vivo. (A) Fold up-regulation of CD86, CD83, CD274, CD40, and HLA-DR on CD1c1 cDCs (top),
CD3031 pDCs (middle), and CD1411 cDCs (bottom). HuNSG mice were injected intraperitoneally with 50 mg/mouse polyICLC, 20 mg/mouse GLA IDC 1001, 25 mg/mouse
protamine/RNA, 20 mg/mouse R848, and 50 mg/mouse CpG ODN 2216 or PBS. At 14 hours after injection, splenocytes were isolated and stained for flow cytometry. Fold up-
regulation was calculated from the mean fluorescence intensity (MFI) in relation to the mean of the corresponding PBS samples. The graph represents composite data from
5 independent experiments. Each data point represents one individually analyzed mouse. Statistical analysis was performed with the Mann-Whitney U test. (B)
Immunohistochemistry for DC markers on spleen sections. HuNSG mice were injected with PBS (top) or with polyICLC (bottom) and euthanized after 14 hours. DEC-205
serves as a DC marker and DC-LAMP and HLA-DR as DC maturation markers.
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mice, and reconstitution levels of DC subsets were more homo-
geneous than these variations in cytokine production. Surprisingly,
GLA did not elicit even low human cytokine levels, despite its
capacity to mature CD1c1 cDCs (Figure 2A).
This ﬁnding suggests that RNA receptor (TLR3/7/8) ligation fully
matures human cDCs and pDCs with up-regulation of costimulatory
molecules and cytokine production, whereas TLR4 and 9 agonists
only partially mature DCs in this experimental setting. Particularly,
TLR4 agonists seem to be poor activators of cytokine production by
constitutive human DC subsets but potently activate mouse DCs to
produce IL-6 and IL-12 (supplemental Figure 3A).
Depletion of CD1411 cDCs reduces IFN-a levels in the serum
of huNSG mice
Because polyICLC, which mainly matures cDCs (Figure 2A),
induced similar serum levels of IFN-a as detected after injection of
the pDC activating TLR ligand R848 (Figure 3D), we hypothesized
that human cDCs could be a nonrecognized source for considerable
amounts of IFN-a. Furthermore, polyICLC matured both human
cDC subsets and led to IFN-a production in vivo, whereas GLA
matured only CD1c1 cDCs without detectable cytokine secretion
(Figures 2A and 3D), suggesting that the CD1411 cDC subset could
be producing the IFN-a. To test this, we depleted CD1411 cDCs in
huNSGmice by injecting an antibody recognizing the CD1411 cDC-
speciﬁc molecule Clec9A.31,32 Depletion of CD1411 cDCs was
transient and partial (Figure 4A) and left the other DC populations
mostly unaltered (supplemental Figure 3B). Subsequently, we
injected polyICLC and analyzed serum IFN-a levels, only con-
sidering mice showing equal CD86 expression on splenic CD1c1
cDCs (Figure 4B). A decrease in CD1411 cDCs resulted in
signiﬁcantly diminished IFN-a levels (Figure 4C). Taken together,
data generated in huNSG mice strongly suggest that the CD1411
cDC subset is a main source of IFN-a production after stimulation
with synthetic dsRNA.
Human donor-derived CD1411 cDCs are potent producers
of IFN-a
To conﬁrm this hypothesis in a strictly human setting, we isolated
cDCs from peripheral blood mononuclear cells (PBMCs) of healthy
volunteers. We stimulated the cDC and the non-cDC fractions with
GLA, polyICLC, or R848 and analyzed IFN-a in the supernatants.
Indeed, cDCs produced considerable amounts of IFN-a in response
Figure 3. Kinetics of human DC maturation and cytokine production in vivo. (A) Time-course for the up-regulation of maturation markers CD86 and CD83 on splenic DC
subsets. HuNSG mice were injected with polyICLC and euthanized after the indicated time points. PBS-injected mice were sacrificed after 14 hours. Splenocytes were stained
for flow cytometry and MFI for CD86 and CD83 is shown for CD1c1 cDCs (top), CD3031 pDCs (middle), and CD1411 cDCs (bottom). (B) Same as in panel A, showing fold
up-regulation over the mean MFI of the PBS samples. (C) Time-course for serum cytokine levels in huNSG mice after the injection of polyICLC. HuNSG mice were injected
and euthanized as in panel A. Serum cytokine levels were determined for human IL-12p70 (left) and human pan-specific IFN-a (right) by ELISA. Data represent 3 independent
experiments. (D) Cytokine levels in the serum of huNSG mice injected with different TLR agonists. HuNSG mice were injected as in Figure 2A. At 11 hours after injection, mice
were euthanized, and human IL-12p70 (left) as well as human pan-specific IFN-a (right) were determined in the serum by ELISA. Composite data from 5 independent
experiments are shown. Each data point represents one individually analyzed mouse. Statistical analysis was performed with the Mann-Whitney U test.
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to polyICLC (Figure 5A). They secreted much less IFN-a in
response to R848 and, in line with huNSG data, none after GLA
stimulation. The non-cDC fraction produced only low IFN-a levels
in response to polyICLC (Figure 5A), probably originating from
residual cDCs. For R848 stimulation of non-cDCs, we attributed at
least part of the IFN-a to pDCs by intracellular cytokine staining
using ﬂow cytometry (not shown).
We next tested which cDC subset in the human samples produces
the IFN-a. Therefore, we enriched CD1411 cDCs, CD3041 pDCs,
and CD1c1 cDCs sequentially from PBMCs (supplemental
Figure 4A-D); stimulated them with TLR agonists; and measured
IFN-a in the supernatants. Because of the low CD1411 cDC
recovery, we only tested polyICLC stimulation for this subset,
whereas the other DC populations were incubated with all TLR
stimuli. CD1411 cDC supernatants contained by far the greatest
concentration of IFN-a after polyICLC stimulation (Figure 5B).
Despite donor variation, CD1411 cDCs of all donors tested
produced high amounts of IFN-a in response to polyICLC. Only
with R848 did pDCs produce IFN-a copiously (Figure 5B-C). In
contrast, CD1c1 cDCs did not secrete IFN-a after stimulation with
GLA (Figure 5B-C), which is the TLR agonist inducing strong up-
regulation of maturation markers on CD1c1 cDCs in huNSG mice
(Figure 2A). We also established an intracellular cytokine staining
for IFN-a in CD1411 cDCs. In enriched, polyICLC-stimulated
cDCs, we detected an IFN-a2speciﬁc signal in CD1411 cDCs
(Figure 5D), which was signiﬁcantly greater than the fold-increase
in CD1c1 cDCs (Figure 5E). Moreover, we compared the IFN-a
subtypes produced by pDCs after stimulation with R848 in contrast
to polyICLC-stimulated CD1411 cDCs. Although pDCs produced
50% of IFN-a2, this subtype only accounts for 5% of the IFN-a
produced by CD1411 cDCs (Figure 5F). This ﬁnding was reﬂected
in the transcriptional proﬁles of CD1411 cDCs, which revealed
a much broader IFN-a repertoire than pDCs, with very low IFN-a2
transcription (Figure 5G-H). Thus, CD1411 cDCs from human
blood produce signiﬁcant amounts of IFN-a, in response to TLR3
stimulation, that consist of other IFN-a subtypes than those
produced by pDCs in response to TLR7 ligation.
Priming of human CD41 T-cell responses after antigen targeting
to DEC-205
Finally, we tested the ability of this unique CD1411 cDC subset to
prime immune responses in vivo. Because they highly express DEC-
205, we aimed to target them by an aDEC-205 mAb with polyICLC
as an adjuvant that mainly elicits immunostimulatory cytokine
production by this DC subset. To validate speciﬁc targeting, we
injected 5 mg of Alexa-6472labeled aDEC-205 or the labeled
isotype control mAb into huNSG mice. After 3 to 5 hours, we
examined antibody uptake by different splenic DC subsets
(Figure 6A-B). Unlike the isotype mAb, the aDEC-205 mAb
labeled most of the CD1411 cDCs. aDEC-205 also bound other DC
subsets and leukocyte populations, as shown in mice33 and in line
with DEC-205 expression on other human cell populations.34,35
However, labeling by aDEC-205 mAb reached the greatest levels in
CD1411 cDCs among different DC subsets and lineage-positive
cells. This ﬁnding infers that antigens targeted to DEC-205 are
most efﬁciently taken up by CD1411 cDCs and that combining this
antigen formulation with polyICLC that triggers immunostimula-
tory cytokine production by this DC subset should only render
CD1411 DCs capable of priming T-cell responses.
We have previously shown that the combination of poly(I:C) and
DEC-2052targeted antigen elicits peptide-speciﬁc, T-cell responses
against the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1)
in huNSG mice.22 To further characterize this T-cell response, we
repeated the immunization experiment with aDEC-205-EBNA1
mAb but used the more stable polyICLC instead to preferentially
mature CD1411 DCs (supplemental Figure 5A). From the spleno-
cytes of the responding huNSG mice, we cloned the EBNA1-speciﬁc
T cells. Several clones responded to EBNA1 peptides (Figure 7A),
and all were positive for human CD45, CD3, and CD4. Some reacted
to only 1 of 5 EBNA1 peptide subpools (Figure 7B). Notably, these
clones were speciﬁc for different epitopes as they reacted to different
subpools (Figure 7B). This ﬁnding indicates that targeting CD1411
cDCs by linking EBNA1 to DEC-205 with polyICLC as adjuvant
induces T-cell responses with broad epitope speciﬁcities in huNSG
mice.
To evaluate the effector functions of these clones, we generated
autologous lymphoblastoid cell lines (LCLs) because they serve as
an in vitro model for EBV-positive tumors. This was achieved by
infecting huNSG mice from the same reconstitution as the im-
munized mice with EBV and subsequent isolation of LCLs from their
splenocytes. The T-cell clones were incubated with those autologous
or allogeneic LCLs loaded with or without EBNA1 peptides, and
we monitored IFN-g production. Autologous LCLs induced strong
responses of the EBNA1-speciﬁc T-cell clones, whereas allogeneic
LCLs did not (Figure 7C and supplemental Figure 5B). In addition,
we evaluated the cytotoxic potential of these clones toward LCLs. In
line with IFN-g secretion, they expressed the degranulation marker
CD107a in autologous LCL cocultures (Figure 7D and supplemental
Figure 5B). Furthermore, we could block responses of the CD41
T-cell clone c16 by aHLA-DR mAb but not aHLA-class I mAb,
indicating that the T-cell response toward LCLs is strictly HLA class
Figure 4. Depletion of human CD141-positive DCs reduces IFN-a levels after
polyICLC stimulation in huNSG mice. (A) CD1411 cDC depletion efficiency in
huNSG mice. HuNSG mice were injected with PBS or 10 mg of aClec9A antibody
intraperitoneally on 3 consecutive days. At 10 hours after the last injection, mice
were injected with polyICLC and euthanized 11 hours later. Splenocytes were
stained for flow cytometry, and the percentage of CD1411 cDCs within the CD11c-
positive gate was determined. (B) CD1c1 cDC maturation in huNSG mice without
and with CD1411 cDC depletion. Same as in panel A with flow cytometry staining for
CD86 on CD1c1 cDCs. (C) Serum levels of IFN-a in huNSG mice without and with
CD1411 cDC depletion. After injections, as in panel A, serum cytokine levels were
determined for human pan-specific IFN-a by ELISA. Left, a representative
experiment; right, plot: composite data from 3 experiments. Each data point
represents one individually analyzed mouse. Statistical analysis was performed with
the Mann-Whitney U test.
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II restricted (Figure 7E). Taken together, this ﬁnding suggests that
targeting antigen to DEC-205 in combination with a strong
stimulus for CD1411 cDC activation as adjuvant elicits CD41
T-cell responses with protective function against autologous EBV-
transformed B cells. In addition, it reports for the ﬁrst time at the
clonal-level, antigen-speciﬁc CD41 T-cell responses in mice with
reconstituted human immune system components.
Discussion
This study shows that DCs reconstituted in huNSG mice resemble
their counterparts in humans. Human CD1c1 cDCs respond to the
TLR3 agonist polyICLC, the TLR4 agonist GLA, and the TLR7/8
agonist R848 like in huNSG mice. In contrast, CD1411 cDCs lack
Figure 5. IFN-a production by CD1411 cDCs in response to TLR3 ligand. (A) Human cDCs produce IFN-a in response to polyICLC. PBMCs of 3 donors were separated
into a cDC and a non-cDC fraction by magnetic-activated cell sorting (MACS) separation. Then, 2 3 105 cells were plated and stimulated for 14 hours with 25 mg/mL polyICLC, 5
mg/mL GLA, or 4 mg/mL R848. Pan IFN-a levels were determined in the cell supernatants after 14 hours by the use of ELISA. (B) IFN-a production by DC subsets after
TLR stimulation. PBMCs were sequentially separated into CD1411 cDCs, CD3041 pDCs, and CD1c1 cDCs by MACS separation. A total of 0.25 3 105 cells of the
positive fractions as well as the final negative fraction were plated, stimulated, and IFN-a levels were determined as in panel A. (C) Same as in panel B but showing
composite data from 3 donors. (D) Intracellular staining for IFN-a in CD1411 cDCs stimulated with polyICLC. cDCs were isolated from PBMCs by MACS separation and
stimulated with polyICLC for 9 hours with 10 mg/mL brefeldin A. Cells were stained for surface markers followed by intracellular cytokine staining for IFN-a. Gating was
performed as described in Figure 1A, and plots display the CD1411 cDCs. Numbers indicate the percentage of IFN-a producing cells with (right) and without (left)
polyICLC stimulation. (E) Fold change of intracellular levels of IFN-a in 4 donors. Same as in panel D but shown for the CD1c1 and CD1411 cDCs fractions. Statistical
analysis was performed with a paired t test. (F) IFN-a secretion by DC subsets. Cellular supernatants shown in panel C were run on pan-IFN-a2specific and IFN-a22
specific ELISAs in parallel. The plot shows composite data for the percentage of IFN-a2 of the pan IFN-a amount for 3 donors. Error bars indicate SD. (G)
Transcriptional profiles for IFN-a subtypes in CD1411 cDCs. CD1411 cDCs were isolated from 3 donors by MACS and stimulated with polyICLC for 8 hours before RNA
isolation. Sybr-green based Q-PCR was performed for the different IFN-a subtypes and transcript numbers were related to 1000 GAPDH copies. Results are displayed
as percentage of the indicated IFN-a subtype transcript number in relation to the total IFN-a count. Error bars indicate SD. (H) Same as in panel H but for CD3041 pDCs
stimulated with R848 for 1 hour.
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TLR4 and are therefore unresponsive to GLA. Because high IL-
12p70 production is a hallmark of CD1411 conventional DCs,8,9
we mainly observed it in response to dsRNA that matures this
particular subset of human cDCs. As anticipated, pDCs up-regulate
maturation markers after TLR7 stimulation with R848. However,
in our hands weaker TLR7/8 agonists, such as protamine/RNA,
and TLR9 agonists, such as CpG, did not mature pDCs. Therefore,
RNA receptor engagement seems to be most efﬁcient for human
DC stimulation in vivo.
Interestingly, we observed not only robust human IL-12p70
production in response to TLR3 ligation but also efﬁcient IFN-a
production, which could not be enhanced upon R848-mediated
maturation of pDCs (data now shown). Although murine IFN-a in
response to poly(I:C) stimulation is mainly produced by non-
hematopoietic cells,25,36 huNSG mice lack human nonhematopoietic
tissues and, therefore, produce signiﬁcant human IFN-a amounts
with their hematopoietic cells. Among human hematopoietic cells,
CD1411 cDCs have been proposed as type I and III IFN sources,
producing IFN-b and -l, respectively.8,37
In addition, we report here that this subset is also a prominent
source of IFN-a after dsRNA stimulation in vitro and in vivo. In
vivo, polyICLC stimulation leads to similar serum IFN-a levels in
huNSG mice as observed in healthy volunteers, namely 5 ng/mL.38
This ﬁnding correlates with phenotypic maturation of CD1411 cDC
maturation and reaches similar levels as R848 stimulation. Of note,
extrapolating from all analyzed organs, the total cell number of
CD1411 cDCs should be 43 lower than for pDCs in huNSG mice,
yet these cells raise serum IFN-a concentrations to similar levels.
Furthermore, in peripheral blood of healthy human donors, IFN-a
production upon polyICLC stimulation resides mainly in cDCs,
especially after CD141 enrichment. Of note, CD1411 cell-enriched
populations produce similar IFN-a levels as pDCs after R848
stimulation. Therefore, CD1411 cDCs have the dual capacity to
produce IL-12p70 and type I IFN, which makes them an attractive
adjuvant target. RNA receptor ligands could serve as agonists to
mature this cDC subset during vaccination.
Apart from harnessing CD1411 cDCs for vaccination, it would
be interesting to assess their contribution to IFN-a production in an
infection model. However, this is hampered by the transient nature
of CD1411 cDC depletion in huNSG mice. Of note, this ﬁnding is
in line with the fast repopulation of DCs after diphtheria toxin
injection in CD11c-DTR transgenic mice.39 Furthermore, most
infectious agents activate multiple cell types by various TLRs,
which would mask the effect of CD1411 cDC after stimulation by
dsRNA molecules. However, one could also envision a role of
CD1411 cDC in resolving viral infection independent of absolute
IFN-a production. As shown (Figure 5F-H), pDCs mainly produce
IFN-a2 and IFN-a14. CD1411 cDCs, on the other hand, secrete
several IFN-a subtypes, which could be needed to orchestrate
a protective immune response against certain viral infections.
Although it remains so far unclear whether functional CD1411
cDCs also reconstitute in other immune-compromised mouse
strains, reconstituted NOD-scid mice have cDCs (lin–CD11c1
HLA-DR1) and pDCs (lin–IL-3R1HLA-DR1).40-42 Although they
develop less DCs outside the BM than huNSG mice (this study and
Ishikawa et al43), human DCs from reconstituted NOD-scid mice
can stimulate alloreactive human T-cell responses in vitro.40-43
Furthermore, they up-regulate maturation markers and secrete IFN-
a upon inﬂuenza virus infection40 and produce IL-12 after the
administration of lipopolysaccharide41 or poly(I:C).42 Because
functional human DCs reconstitute in immune compromised mice
but NSG mice reconstitute especially high numbers of all human
constitutive DC populations in spleen and blood, huNSG mice
should be further explored for vaccine development.
We had previously observed that antigen targeted to DEC-205
on DCs with poly(I:C) as adjuvant induced IFN-g2producing
T cells in huNSG mice.22 Similarly, polyICLC plus DEC-205-
targeted antigen elicited T-cell responses in nonhuman primates,44
and in this study, CD41 T-cell responses in huNSGmice. Although
antigen-speciﬁc CD81 T-cell responses have been documented in
mice with reconstituted human immune system components,20,45-47
our study shows for the ﬁrst time antigen-speciﬁc CD41 T-cell
responses, which could be veriﬁed at the clonal level, in one of these
models. Interestingly, both DEC-205 and TLR3 expression are
greatest on human CD1411 cDCs (Robbins et al10 and this study),
and, therefore, this antigen/adjuvant formulation might preferentially
Figure 6. aDEC-A647 is taken up most efficiently
by CD1411 cDCs in vivo. (A) 5 mg of aDEC-A647 or
IgG-A647 was injected intraperitoneally into huNSG
mice. After 3 hours, the mice were euthanized, and
antibody uptake into the different cellular subsets in the
spleen was analyzed by fluorescence-activated cell
sorting. (B) Same as in panel A but shown for mice
from 2 independent experiments, including 3- and 5-
hour time points, which showed similar results. Each
data point represents one individually analyzed mouse.
Statistical analysis was performed with paired t tests.
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harnesses this small, but potent DC population for vaccination.
Indeed, DEC-205 targeting of antigens to the mouse counterpart
of CD1411 cDCs, CD8a1 cDCs, enhances priming of T-cell
responses 100-fold, and the targeting to other receptors like
Langerin and CLEC9A on CD8a1 cDCs similarly augments
vaccine-induced immune responses.33 With the additional IFN-a
production by this DC subset in humans, it becomes even more
attractive for vaccine development. Furthermore, the role of
CD1411 cDCs in innate and adaptive immunity to important
human pathogens as well as in inducing tolerance in autoimmune
settings could be explored in huNSG mice. In addition, they should
be important tools to test vaccine regiments in a preclinical setting
Figure 7. Characterization of T-cell responses induced by vaccination with aDEC-205-EBNA1 and polyICLC in huNSG mice. (A) aDEC-205-EBNA1 plus polyICLC
vaccination primes specific T cells in huNSG mice. HuNSG mice were vaccinated with 5 mg of IgG-EBNA1 or aDEC-205-EBNA1 with the use of 50 mg of polyICLC as adjuvant
and boosted with the same dose of antibodies and adjuvant 4 weeks later. The mice were euthanized 6 to 8 weeks after the boost. T-cell clones were generated by limiting
dilution cloning of specific T cells after an IFN-g capture assay after restimulation with 5mM EBNA1 peptide library for 12 hours. IFN-g secretion was analyzed by ELISA in the
supernatant. (B) The specificity of 3 expanded T-cell clones (c15, c16, c21) are shown after restimulation with 5 different peptide subpools of EBNA1 by measuring IFN-g
secreted into the supernatant. Data are represented as mean 6 SD from duplicate or triplicate wells of IFN-g ELISA. (C) The EBNA1 specific T-cell clone c16 recognizes
autologous LCLs. Autologous LCLs (Auto LCL) or allogeneic LCLs (Allo LCL), unmanipulated or loaded for 1 hour with 5mM EBNA1 peptides, were incubated with the
expanded EBNA1-specific T-cell clone c16 (E:T51:2), T-cell activity was determined after 18 hours by measuring released IFN-g by ELISA. (D) Same as in panel C but
analyzing T-cell function by CD107a staining after 6 hours of coculture. (E) The T-cell response of clone c16 is MHC class II-restricted. T-cell clone c16 was exposed to the
autologous LCLs in the absence or presence of the indicated HLA blocking antibodies and IFN-g was measured in the supernatants by ELISA. One representative experiment
of 2 is shown. Statistical analysis was performed by Mann-Whitney U tests, and data are represented as mean 6 SD.
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with hopefully improved predictive value for immunogenicity in
humans.
Acknowledgments
This work was supported by grants to C.M. from the National Cancer
Institute (R01CA108609), the Sassella Foundation (10/02, 11/02 and
12/02), Cancer Research Switzerland (KFS-02652-08-2010), the
Association for International Cancer Research (11-0516), KFSPMS
and KFSPHLD of the University of Zurich, the Vontobel Foundation,
the Baugarten Foundation, the EMDO Foundation, the Sobek
Foundation, Fondation Acteria, Novartis, and the Swiss National
Science Foundation (310030_143979 and CRSII3_136241). S.M.,
C.S.L., and P.C.R. were supported by junior research fellowships from
the University of Zu¨rich. C.S.L. was also supported by the Croucher
Foundation Hong Kong.
Authorship
Contribution: S.M. and C.S.L. designed and performed research;
P.C.R., M.P., and L.D.V. performed experiments; R.M.S. and C.M.
designed research; G.B., S.P., A.M.S., A.D., and J.S. contributed
essential information or vital reagents; and S.M., C.S.L., and C.M.
wrote the manuscript.
Conﬂict-of-interest disclosure: A.M.S. heads Oncovir Inc.,
which provided polyICLC. A.D. and J.S. work for Miltenyi Biotec,
which provided the anti-Clec9A antibody. The remaining authors
declare no competing ﬁnancial interests.
Ralph M. Steinman died on September 30, 2011.
Correspondence: Christian Mu¨nz, Viral Immunobiology, In-
stitute of Experimental Immunology, University of Zu¨rich, Winter-
thurerstrasse 190, CH-8057 Zu¨rich, Switzerland; e-mail: christian.
muenz@uzh.ch.
References
1. Steinman RM, Banchereau J. Taking dendritic
cells into medicine. Nature. 2007;449(7161):
419-426.
2. Steinman RM. Decisions about dendritic cells:
past, present, and future. Annu Rev Immunol.
2012;30:1-22.
3. Palucka K, Banchereau J, Mellman I. Designing
vaccines based on biology of human dendritic cell
subsets. Immunity. 2010;33(4):464-478.
4. MacDonald KP, Munster DJ, Clark GJ, Dzionek A,
Schmitz J, Hart DN. Characterization of human
blood dendritic cell subsets. Blood. 2002;100(13):
4512-4520.
5. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2,
BDCA-3, and BDCA-4: three markers for distinct
subsets of dendritic cells in human peripheral
blood. J Immunol. 2000;165(11):6037-6046.
6. Coffman RL, Sher A, Seder RA. Vaccine
adjuvants: putting innate immunity to work.
Immunity. 2010;33(4):492-503.
7. Iwasaki A, Medzhitov R. Toll-like receptor control
of the adaptive immune responses. Nat Immunol.
2004;5(10):987-995.
8. Jongbloed SL, Kassianos AJ, McDonald KJ, et al.
Human CD1411 (BDCA-3)1 dendritic cells (DCs)
represent a unique myeloid DC subset that cross-
presents necrotic cell antigens. J Exp Med. 2010;
207(6):1247-1260.
9. Poulin LF, Salio M, Griessinger E, et al.
Characterization of human DNGR-11 BDCA31
leukocytes as putative equivalents of mouse
CD8alpha1 dendritic cells. J Exp Med. 2010;
207(6):1261-1271.
10. Robbins SH, Walzer T, Dembe´le´ D, et al. Novel
insights into the relationships between dendritic
cell subsets in human and mouse revealed by
genome-wide expression profiling. Genome Biol.
2008;9(1):R17.
11. Bachem A, Gu¨ttler S, Hartung E, et al. Superior
antigen cross-presentation and XCR1 expression
define human CD11c1CD1411 cells as
homologues of mouse CD81 dendritic cells. J Exp
Med. 2010;207(6):1273-1281.
12. Crozat K, Guiton R, Contreras V, et al. The XC
chemokine receptor 1 is a conserved selective
marker of mammalian cells homologous to mouse
CD8alpha1 dendritic cells. J Exp Med. 2010;
207(6):1283-1292.
13. Ra¨mer PC, Chijioke O, Meixlsperger S, Leung
CS, Mu¨nz C. Mice with human immune system
components as in vivo models for infections with
human pathogens. Immunol Cell Biol. 2011;89(3):
408-416.
14. Legrand N, Ploss A, Balling R, et al. Humanized
mice for modeling human infectious disease:
challenges, progress, and outlook. Cell Host
Microbe. 2009;6(1):5-9.
15. Ishikawa F, Yasukawa M, Lyons B, et al.
Development of functional human blood and
immune systems in NOD/SCID/IL2 receptor
gamma chain(null) mice. Blood. 2005;106(5):
1565-1573.
16. Traggiai E, Chicha L, Mazzucchelli L, et al.
Development of a human adaptive immune
system in cord blood cell-transplanted mice.
Science. 2004;304(5667):104-107.
17. Shultz LD, Lyons BL, Burzenski LM, et al. Human
lymphoid and myeloid cell development in NOD/
LtSz-scid IL2R gamma null mice engrafted with
mobilized human hemopoietic stem cells.
J Immunol. 2005;174(10):6477-6489.
18. Melkus MW, Estes JD, Padgett-Thomas A, et al.
Humanized mice mount specific adaptive and
innate immune responses to EBV and TSST-1.
Nat Med. 2006;12(11):1316-1322.
19. Tanaka S, Saito Y, Kunisawa J, et al.
Development of mature and functional human
myeloid subsets in hematopoietic stem cell-
engrafted NOD/SCID/IL2rgKO mice. J Immunol.
2012;188(12):6145-6155.
20. Strowig T, Gurer C, Ploss A, et al. Priming of
protective T cell responses against virus-induced
tumors in mice with human immune system
components. J Exp Med. 2009;206(6):1423-1434.
21. Puig M, Tosh KW, Schramm LM, et al. TLR9 and
TLR7 agonists mediate distinct type I IFN
responses in humans and nonhuman primates in
vitro and in vivo. J Leukoc Biol. 2012;91(1):
147-158.
22. Gurer C, Strowig T, Brilot F, et al. Targeting the
nuclear antigen 1 of Epstein-Barr virus to the
human endocytic receptor DEC-205 stimulates
protective T-cell responses. Blood. 2008;112(4):
1231-1239.
23. Leung CS, Haigh TA, Mackay LK, Rickinson AB,
Taylor GS. Nuclear location of an endogenously
expressed antigen, EBNA1, restricts access to
macroautophagy and the range of CD4 epitope
display. Proc Natl Acad Sci U S A. 2010;107(5):
2165-2170.
24. Pack M, Trumpfheller C, Thomas D, et al.
DEC-205/CD2051 dendritic cells are abundant in
the white pulp of the human spleen, including the
border region between the red and white pulp.
Immunology. 2008;123(3):438-446.
25. Longhi MP, Trumpfheller C, Idoyaga J, et al.
Dendritic cells require a systemic type I interferon
response to mature and induce CD41 Th1
immunity with poly IC as adjuvant. J Exp Med.
2009;206(7):1589-1602.
26. Stahl-Hennig C, Eisenbla¨tter M, Jasny E, et al.
Synthetic double-stranded RNAs are adjuvants
for the induction of T helper 1 and humoral
immune responses to human papillomavirus in
rhesus macaques. PLoS Pathog. 2009;5(4):
e1000373.
27. Coler RN, Bertholet S, Moutaftsi M, et al.
Development and characterization of synthetic
glucopyranosyl lipid adjuvant system as a vaccine
adjuvant. PLoS ONE. 2011;6(1):e16333.
28. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or
TLR8 independently confer responsiveness to the
antiviral compound R-848. Nat Immunol. 2002;
3(6):499.
29. Scheel B, Teufel R, Probst J, et al. Toll-like
receptor-dependent activation of several human
blood cell types by protamine-condensed mRNA.
Eur J Immunol. 2005;35(5):1557-1566.
30. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like
receptor recognizes bacterial DNA. Nature. 2000;
408(6813):740-745.
31. Sancho D, Moura˜o-Sa´ D, Joffre OP, et al. Tumor
therapy in mice via antigen targeting to a novel,
DC-restricted C-type lectin. J Clin Invest. 2008;
118(6):2098-2110.
32. Huysamen C, Willment JA, Dennehy KM, Brown
GD. CLEC9A is a novel activation C-type lectin-
like receptor expressed on BDCA31 dendritic
cells and a subset of monocytes. J Biol Chem.
2008;283(24):16693-16701.
33. Idoyaga J, Lubkin A, Fiorese C, et al. Comparable
T helper 1 (Th1) and CD8 T-cell immunity by
targeting HIV gag p24 to CD8 dendritic cells within
antibodies to Langerin, DEC205, and Clec9A.
Proc Natl Acad Sci USA. 2011;108(6):2384-2389.
34. Kato M, McDonald KJ, Khan S, et al. Expression
of human DEC-205 (CD205) multilectin receptor
on leukocytes. Int Immunol. 2006;18(6):857-869.
35. Leung CS, Maurer MA, Meixlsperger S, et al.
Robust T cell stimulation by Epstein-Barr virus-
transformed B cells after antigen targeting to
DEC-205. Blood. 2013;121:1584-1594.
36. Gitlin L, Barchet W, Gilfillan S, et al. Essential
role of mda-5 in type I IFN responses to
polyriboinosinic:polyribocytidylic acid and
encephalomyocarditis picornavirus. Proc Natl
Acad Sci USA. 2006;103(22):8459-8464.
BLOOD, 20 JUNE 2013 x VOLUME 121, NUMBER 25 IFN-a PRODUCTION BY HUMAN CONVENTIONAL DCs 5043
 For personal use only. at Universitaet Zurich on June 21, 2013. bloodjournal.hematologylibrary.orgFrom 
37. Lauterbach H, Bathke B, Gilles S, et al. Mouse
CD8alpha1 DCs and human BDCA31 DCs are
major producers of IFN-lambda in response to
poly IC. J Exp Med. 2010;207(12):2703-2717.
38. Caskey M, Lefebvre F, Filali-Mouhim A, et al.
Synthetic double-stranded RNA induces innate
immune responses similar to a live viral vaccine in
humans. J Exp Med. 2011;208(12):2357-2366.
39. Jung S, Unutmaz D, Wong P, et al. In vivo depletion
of CD11c1 dendritic cells abrogates priming of
CD81 T cells by exogenous cell-associated
antigens. Immunity. 2002;17(2):211-220.
40. Palucka AK, Gatlin J, Blanck JP, et al. Human
dendritic cell subsets in NOD/SCID mice
engrafted with CD341 hematopoietic progenitors.
Blood. 2003;102(9):3302-3310.
41. Cravens PD, Melkus MW, Padgett-Thomas A,
Islas-Ohlmayer M, Del P Martin M, Garcia JV.
Development and activation of human dendritic
cells in vivo in a xenograft model of human
hematopoiesis. Stem Cells. 2005;23(2):264-278.
42. Vuckovic S, Abdul Wahid FS, Rice A, et al.
Compartmentalization of allogeneic T-cell
responses in the bone marrow and spleen of
humanized NOD/SCID mice containing activated
human resident myeloid dendritic cells. Exp
Hematol. 2008;36(11):1496-1506.
43. Ishikawa F, Niiro H, Iino T, et al. The
developmental program of human dendritic cells
is operated independently of conventional myeloid
and lymphoid pathways. Blood. 2007;110(10):
3591-3660.
44. Flynn BJ, Kastenmu¨ller K, Wille-Reece U, et al.
Immunization with HIV Gag targeted to dendritic
cells followed by recombinant New York vaccinia
virus induces robust T-cell immunity in nonhuman
primates. Proc Natl Acad Sci USA. 2011;108(17):
7131-7136.
45. Shultz LD, Saito Y, Najima Y, et al. Generation
of functional human T-cell subsets with HLA-
restricted immune responses in HLA class I
expressing NOD/SCID/IL2r gamma(null)
humanized mice. Proc Natl Acad Sci USA. 2010;
107(29):13022-13027.
46. Jaiswal S, Pazoles P, Woda M, et al. Enhanced
humoral and HLA-A2-restricted dengue
virus-specific T-cell responses in humanized
BLT NSG mice. Immunology. 2012;136(3):
334-343.
47. Brainard DM, Seung E, Frahm N, et al. Induction
of robust cellular and humoral virus-specific
adaptive immune responses in human
immunodeficiency virus-infected humanized
BLT mice. J Virol. 2009;83(14):7305-7321.
5044 MEIXLSPERGER et al BLOOD, 20 JUNE 2013 x VOLUME 121, NUMBER 25
 For personal use only. at Universitaet Zurich on June 21, 2013. bloodjournal.hematologylibrary.orgFrom 
